A team of researchers from the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL) has ...

A team of researchers from the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL) has identified a potential biomarker of Parkinson's disease progression.

According to the new study, published in the NPJ Parkinson's Disease, patients with a slow progression of the pathology would ...

Right now, nearly 1 million people in the U.S. are living with Parkinson's Disease. Playhouse Square is rolling out a new program to help a growing number of patients.

Analysis suggests that the research and development of DMTs and non-motor therapies will diversify Parkinson's treatment ...

There’s still a lot we don’t know about how Parkinson’s disease develops. But one lifestyle intervention already has strong evidence behind it.

Researchers at Tel Aviv University (TAU) discovered a new factor in the pathology of Parkinson's disease, which in the future ...

Vesalius Therapeutics, a company pioneering a revolutionary platform to deliver breakthrough treatments for common diseases, ...

THOSE afflicted with Parkinson’s disease (PD) must contend with tremors, stiffness, and uncontrollable movements in their body as a result of the deterioration of their nervous system. Proper care is ...

GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

Subscribe to Here’s the Deal, our politics newsletter for analysis you won’t find anywhere else.

Galantamine slowed decline in cognitive function, functional ability, and behavior at 6 months in people with Alzheimer's ...